Seribantumab
As of the edition of 20 October 2026, Seribantumab is an antibody: stopped in 2024; acts on ERBB3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Antibody
- Registered trials
- 14, 4 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Lungs and airways; Digestive system; Hormones; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Seribantumab.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ERBB3 | Receptor tyrosine-protein kinase erbB-3 | P21860 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 5 | 0 | 1 |
| Phase 2 | 8 | 5 | 0 | 3 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merrimack Pharmaceuticals | Lead sponsor of trials | 2008 to now |
| Sanofi | Lead sponsor of trials | 2011 to now |
| Concentra Biosciences | Lead sponsor of trials | 2015 to now |